Dr. Louis Lacombe is a urologist-oncologist and clinical researcher at the CHU de Québec, and more specifically at L’Hôtel-Dieu de Québec.

Dr. Lacombe completed his medical training in Sherbrooke in 1988 and then completed a specialization in Urology at Laval University in 1993. Subsequently, Dr. Lacombe traveled to New York at the Memorial Sloan-Kettering Cancer Center associated with Cornell University to perform a subspecialisation in uro-oncology. This subspecialisation ended in 1996.

Following this subspecialisation, Dr. Lacombe joined the Urology Department of the CHU de Québec in July 1996. As a urologist, Dr. Lacombe specializes in complex surgeries associated with prostate, kidney, testicular and bladder cancer. He also collaborates in kidney transplant surgery.

Research at the Experimental Uro-oncology Laboratory aims to improve the diagnosis, prognosis, and therapy of prostate, bladder, and kidney cancers, and thus cover many aspects of research, from basic research to applied research. His interest is mainly focused on bladder cancer.

Dr. Lacombe is also actively involved in clinical research by conducting numerous Phase I, Phase II or Phase III clinical trials to test new drugs or therapies. He has been the principal investigator or co-investigator in more than 120 studies since the beginning of his career.

He has published more than 110 scientific papers and more than 250 scientific abstracts, and has presented at many international conferences.

Throughout his career, he has been awarded the FRQS Junior I and II Clinician Fellowship. He is currently a full professor in the Department of Surgery, and since 2016 he is the Director of the University Department of Surgery at the School of Medicine at Laval University.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.613
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67698
+1 418-691-3154
Louis.Lacombe@crchudequeb...

Latest news

170 entries « ‹ 1 of 17 › »

Dahmani C, Caron P, Simonyan D, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C

Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer

Journal Article

J Urol, 209 (2), 2023.

Abstract | Links:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Journal Article

Cancer Lett, 553 , 2023.

Abstract | Links:

Rouleau M, Nguyen Van Long F, Turcotte V, Caron P, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C

Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer

Journal Article

Br J Cancer, 128 (2), 2023.

Abstract | Links:

Fadel J, Simonyan D, Fradet V, Lodde M, Lacombe L, Fradet Y, Toren P

Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer

Journal Article

Urol Oncol, 40 (12), 2022.

Abstract | Links:

Rouleau M, Neveu B, Caron P, Morin F, Toren P, Lacombe L, Turcotte V, Lévesque É, Guillemette C, Pouliot F

Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level

Journal Article

J Urol, 208 (6), 2022.

Abstract | Links:

Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Journal Article

J Immunother Cancer, 10 (8), 2022.

Abstract | Links:

Ravindran A, Krieger KL, Kaushik AK, Hovington H, Mehdi S, Piyarathna DWB, Putluri V, Basil P, Rasaily U, Gu F, Dang T, Choi JM, Sonavane R, Jung SY, Wang L, Mehra R, Weigel NL, Putluri N, Rowley DR, Palapattu GS, Guillemette C, Lacombe L, Lévesque É, Sreekumar A

Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients

Journal Article

Cells, 11 (15), 2022.

Abstract | Links:

Turcotte B, Bélanger L, Blais AS, Blouin AC, Bolduc S, Bolduc-Mokhtar A, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Gaudreau N, Lacombe L, Moore K, Morin F, Nadeau G, Paquet S, Simard F, Simonyan D, Soucy F, Tiguert R, Toren P, Lodde M, Pouliot F

Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspective

Journal Article

Can Urol Assoc J, 16 (10), 2022.

Abstract | Links:

Frégeau-Proulx L, Lacouture A, Berthiaume L, Weidmann C, Harvey M, Gonthier K, Pelletier JF, Neveu B, Jobin C, Bastien D, Bergeron A, Fradet Y, Lacombe L, Laverdière I, Atallah C, Pouliot F, Audet-Walsh É

Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

Journal Article

Mol Metab, 62 , 2022.

Abstract | Links:

Berrehail Z, Boibessot C, Gris T, Joncas FH, Gaignier F, Guillemette C, Lacombe L, Fradet Y, Toren P

Sex steroid modulation of macrophages within the prostate tumor microenvironment

Journal Article

Am J Clin Exp Urol, 10 (2), 2022.

Abstract | Links:

170 entries « ‹ 1 of 17 › »
Signaler des ajouts ou des modifications

Active projects

  • Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, from 2021-09-01 to 2023-08-31
  • Soutien à la recherche, from 2017-07-01 to 2024-06-30
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30

Recently finished projects

  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression, from 2019-04-01 to 2022-03-30
Data provided by the Université Laval research projects registery